

## References

### S-124

1. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC. Organ Procurement and Transplantation Network Policies. 2020; <https://optn.transplant.hrsa.gov>.
2. National Kidney Foundation. Glomerular Filtration Rate (GFR). n.d.; <https://www.kidney.org/atoz/content/gfr>.
3. American Society of Transplant Surgeons (ASTS), The American Society of Transplantation (AST), The Association of Organ Procurement Organizations (AOPO), et al. Statement on transplantation of organs from HIV-infected deceased donors.
4. Kervinen, MG, Lehto S, Helve J, et al. Type 2 diabetic patients on renal replacement therapy: Probability to receive renal transplantation and survival after transplantation. *PLoS One*. 2018 15;13(8):e0201478.
5. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. *Ann Transl Med*. 2018;6(20):409.
6. Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta analysis. *BMJ*. 2022;376:e068769.
7. Zheng X, Gong L, Xue W, et al. Kidney transplant outcomes in HIV-positive patients: A systematic review and meta-analysis. *AIDS Res Ther*. 2019;16(1):37.
8. Kainz A, Kammer M, Reindl-Schwaighofer R, et al. Waiting time for second kidney transplantation and mortality. *Clin J Am Soc Nephrol*. 2022;17(1):90-97.
9. Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis c infected kidneys into uninfected recipients: A single-group trial. *Ann Intern Med*. 2018;169(5):273-281.
10. Durand CM, Bowring MG, Brown DM, et al. Direct-Acting antiviral prophylaxis in kidney transplantation from hepatitis c virus-infected donors to noninfected recipients: An open-label nonrandomized trial. *Ann Intern Med*. 2018;168(8):533-540.
11. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis c-infected kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis c virus infection. *J Am Soc Nephrol*. 2020;31(11):2678-2687.

12. Sise ME, Goldberg DS, Schaubel DE, et al. One-year outcomes of the multi-center study to transplant hepatitis c-infected kidneys (MYTHIC) Trial. *Kidney Int Rep.* 2021;7(2):241-250.
13. Gupta G, Yakubu I, Bhati CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. *Am J Transplant.* 2020;20(3):739-751.
14. Franco A, Moreso F, Merino E, et al. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: A prospective study. *Transpl Int.* 2019;32(7):710-716.
15. Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience. *Hepatology.* 2020;72(1):32-41.
16. Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, openlabel study [published correction appears in *Lancet Gastroenterol Hepatol.* 2020 Jul;5(7):e6]. *Lancet Gastroenterol Hepatol.* 2020;5(7):649-657.
18. Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. *Am J Transplant.* 2019;19(11):3046-3057.
20. Friebus-Kardash J, Gäckler A, Kribben A, et al. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. *Transpl Infect Dis.* 2019;21(5):e13146.
21. Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience. *Transpl Infect Dis.* 2021;23(3):e13540.
22. Alghamdi W, Lotfy K, Weernink C, et al. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: Ready for prime time. *BMC Gastroenterol.* 2022;22(1):34.
23. Kainz A, Kammer M, Reindl-Schwaighofer R, et. al. Waiting time for second kidney transplantation and mortality. *Clin zJ Am Soc Nephrol.* 2022; 17(1): 90-97.
24. Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta-analysis. 2022; 1;376:e068769.